Antiplatelet potencies of polysaccharides extracted from eight cultivated edible Pleurotus mushroom species
Type
Journal article
Language
English
Date issued
2025
Author
Poniedziałek, Barbara
Komaniecka, Iwona
Wiater, Adrian
Choma, Adam
Rosińska, Joanna
Rzymski, Piotr
Faculty
Wydział Rolnictwa, Ogrodnictwa i Biotechnologii
Wydział Inżynierii Środowiska i Inżynierii Mechanicznej
PBN discipline
agriculture and horticulture
environmental engineering, mining and energy
Journal
Pharmacological Reports
ISSN
1734-1140
Volume
77
Number
4
Pages from-to
1109–1118
Abstract (EN)
Background
Cardiovascular diseases remain a leading global health challenge, necessitating effective antiplatelet therapies to mitigate thrombotic risks. Conventional antiplatelet agents, such as acetylsalicylic acid (ASA) and purinergic receptor type Y, subtype 12 (P2Y12) inhibitors, are effective but present limitations, including bleeding complications and resistance in some patients. This study investigates the antiplatelet potential of polysaccharide fractions extracted from fruiting bodies of eight different edible Pleurotus mushroom species cultivated for the purpose of this research.
Methods
Mushroom polysaccharide fractions were extracted from eight Pleurotus species (P. citrinopileatus, P. columbinus, P. djamor, P. eryngii, P. florida, P. ostreatus, P. pulmonarius, and P. sajor-caju) with cold water. Using multiple electrode aggregometry, we evaluated their inhibitory effects on platelet aggregation induced by adenosine-5′-diphosphate (ADP) and arachidonic acid (AA).
Results
Polysaccharides from all tested Pleurotus species exhibit significant inhibition of ADP-induced platelet aggregation in the 69–75% range, comparable to or exceeding that of ASA. While their beneficial effect on AA-induced aggregation was lower and limited to selected species with inhibition in the 6–46% range, polysaccharides from P. djamor and P. sajor-caju demonstrated promising dual inhibition.
Conclusions
This study suggests that Pleurotus-derived polysaccharides may serve as potential natural alternatives or adjuncts to existing antiplatelet therapies. Further in vivo studies and clinical trials are warranted to investigate their therapeutic potential in the prevention and management of cardiovascular disease.
Cardiovascular diseases remain a leading global health challenge, necessitating effective antiplatelet therapies to mitigate thrombotic risks. Conventional antiplatelet agents, such as acetylsalicylic acid (ASA) and purinergic receptor type Y, subtype 12 (P2Y12) inhibitors, are effective but present limitations, including bleeding complications and resistance in some patients. This study investigates the antiplatelet potential of polysaccharide fractions extracted from fruiting bodies of eight different edible Pleurotus mushroom species cultivated for the purpose of this research.
Methods
Mushroom polysaccharide fractions were extracted from eight Pleurotus species (P. citrinopileatus, P. columbinus, P. djamor, P. eryngii, P. florida, P. ostreatus, P. pulmonarius, and P. sajor-caju) with cold water. Using multiple electrode aggregometry, we evaluated their inhibitory effects on platelet aggregation induced by adenosine-5′-diphosphate (ADP) and arachidonic acid (AA).
Results
Polysaccharides from all tested Pleurotus species exhibit significant inhibition of ADP-induced platelet aggregation in the 69–75% range, comparable to or exceeding that of ASA. While their beneficial effect on AA-induced aggregation was lower and limited to selected species with inhibition in the 6–46% range, polysaccharides from P. djamor and P. sajor-caju demonstrated promising dual inhibition.
Conclusions
This study suggests that Pleurotus-derived polysaccharides may serve as potential natural alternatives or adjuncts to existing antiplatelet therapies. Further in vivo studies and clinical trials are warranted to investigate their therapeutic potential in the prevention and management of cardiovascular disease.
License
Closed Access
Closed Access